Adrenocortical Tumors: Prevalence of Impaired Glucose Tolerance and of “Paradoxical Rise” of Cortisol During an Oral Glucose Tolerance Test

Abstract

Glucose tolerance and the behaviour of cortisol during an oral glucose tolerance test (OGTT) was investigated in 126 patients with adrenal “incidentalomas” (age: > 45 years) and in 129 age-matched controls. Impaired glucose tolerance (IGT) was found to be more common (p < 0.02) among patients with adrenal incidentalomas. Subdividing these patients by their body weight it was found that 29 % (controls: 25 %) of those with normal body weight (BMI 20 - 25 kg/m²) had IGT/DM. In overweight (BMI 25 - 30 kg/m²) and obese patients (BMI 30 - 40 kg/m²) the share of IGT/DM was 32 % (controls: 19 %) and 66 % (controls 42 %), respectively. The prevalence of a “paradoxical” rise in serum cortisol concentrations during the OGTT was slightly higher (p < 0.05) among patients with adrenal incidentaloma than among controls. Patients as well as controls with this abnormal behaviour of cortisol were characterized by lower basal serum cortisol concentrations (p < 0.01) but no association was seen with either the presence of IGT or with post-dexamethasone concentrations of serum cortisol. Thus both in patients with and without adrenal incidentalomas abnormal glucose tolerance is an age- and weight-dependent phenomenon unrelated to the post-prandial behaviour of serum cortisol concentrations.

Key words

Adrenal incidentaloma - adrenal adenoma - impaired glucose tolerance - cortisol - age - body weight

References

• 1 Anderson W A, Kissane J M. Pathology. ed 7. St. Louis; Mosby 1977: 1671-1674
• 2 Andres R. Aging and diabetes.  Med Clin North Amer. 1991;  55 835-846
• 3 Andrews R C, Walker B R. Glucocorticoids and insulin resistance: old hormones, new targets.  Clin Sci. 1999;  96 513-523
• 4 Baumgartner-Parzer S M, Pauschenwein S, Waldhäusl W, Pölzler K, Nowotny P, Vierhapper H. Increased prevalence of heterozygous 21-OH germ line mutations in patients with adrenal incidentalomas.  Clin Endocrinol. 2002;  56 811-816
• 5 Beuschlein F, Borgemeister M, Schirra J, Goke B, Fassnacht M, Arlt W, Allolio B, Reincke M. Oral glucose tolerance testing but not intravenous glucose administration uncovers hyper-responsiveness of hypothalamo-pituitary-adrenal axis in patients with adrenal incidentalomas.  Clin Endocrinol. 2000;  52 617-623
• 6 Biermann E L, Bagdale J D, Porte D. Obesity and diabetes: the odd couple.  Am J Clin Nutr. 1968;  21 1434-1437
• 7 Björntorp P. Visceral obesity: “a civilisation syndrome”.  Obes Res. 1993;  1 206-222
• 8 Dinnen S, Alzaid A, Miles J, Rizza R. Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans.  J Clin Invest. 1993;  92 2283-2290
• 9 Everhart J E, Pettitt D J, Bennett P H, Knowler W C. Duration of obesity increases the incidence of NIDDM.  Diabetes. 1992;  42 235-240
• 10 Fernandez-Real J M, Engel W R, Simo R, Salinas I, Webb S M. Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours.  Clin Endocrinol. 1998;  49 53-61
• 11 Fruehwald-Schultes B, Kern W, Bong W, Wellhoener P, Kerner W, Born J, Fehm H L, Peters A. Supraphysiological hyperinsulinemia acutely increases hypothalamic-pituitary-adrenal secretory activity in humans.  J Clin Endocrinol Metab. 1999;  84 3041-3046
• 12 Garrapa G G, Pantanetti P, Arnaldi G, Mantero F, Faloia E. Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome.  J Clin Endocrinol Metab. 2001;  86 5301-5306
• 13 Harris M I, Hadden W C, Knowler W C, Bennet P H. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20 - 74 yr.  Diabetes. 1987;  36 523-534
• 14 Hedeland H, Ostberg G, Hokfeld B. On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes.  Acta Med Scand. 1968;  184 211-214
• 15 Hosmer D W, Lemeshow S. Applied Logistic Regression. New York; Wiley 1989
• 16 Jarrett R J, McCartney P, Keen H. The Bedford Survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics.  Diabetologia. 1982;  22 79-84
• 17 Korbonits M, Trainer P, Nelson M, Howse I, Kopelman P, Besser G, Grossman A, Svec F. Differential stimulation of cortisol and dehydroepiandrosterone levels by food in obese and normal subjects: relation to body fat distribution.  Clin Endocrinol (Oxf). 1996;  45 699-706
• 18 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
• 19 Mesiano S, Mellon S H, Jaffe R B. Mitogenic action, regulation, and localization of insulin-like growth factors in the human fetal adrenal gland.  J Clin Endocrinol Metab. 1993;  76 968-976
• 20 Midorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T. The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection.  Clin Endocrinol. 2001;  54 797-804
• 21 Reincke M, Nieke J, Krestin G P, Saeger W, Allolio B, Winkelmann W. Preclinical Cushing's Syndrome in adrenal “incidentalomas”: comparison with adrenal Cushing's syndrome.  J Clin Endocrinol Metab. 1992;  75 826-832
• 22 Reincke M, Faßnacht M, Väth S, Mora P, Allolio B. Adrenal incidentalomas: a manifestation of the metabolic syndrome?.  Endocr Res. 1996;  22 757-761
• 23 Ross N S, Aron D C. Hormonal evaluation of the patient with an incidentally discovered adrenal mass.  N Engl J Med. 1990;  323 1402-1405
• 24 Ross N S. Epidemiology of Cushing's syndrome and subclinical disease.  Endocrinol Metab North Am. 1994;  23 539-546
• 25 Rossi R, Tauchmanova L, Luciano A, Dimartino M, Battista C, Delviscovo L, Nuzzo V, Lombardi G. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: Clinical and biochemical features.  J Clin Endocrinol Metab. 2000;  85 1440-1448
• 26 Russi S, Blumenthal H T. Small adenomas of the adrenal cortex in hypertension and diabetes.  Arch Intern Med. 1945;  76 284-291
• 27 Saad M F, Knowler W C, Pettitt D J, Nelson R G, Mott D M, Bennett P H. The natural history of impaired glucose tolerance in the Pima Indians.  New Engl J Med. 1988;  319 1500-1506
• 28 Sluiter W J, Erkelens D W, Reitsma W D, Doorenbos H. Glucose tolerance and insulin release, a mathematical approach I. Assay of the beta-cell response after oral glucose loading.  Diabetes. 1976;  25 241-244
• 29 Terzolo M, Pia A, Ali A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G, Angeli A. Adrenal incidentaloma: A new cause of the metabolic syndrome?.  J Clin Endocrinol Metab. 2002;  87 998-1003
• 30 Vierhapper H. Adrenocortical tumors: clinical symptoms and biochemical diagnosis.  Europ J Radiol. 2002;  41 88-94
• 31 Waldhäusl W, Herkner K, Nowotny P, Bratusch-Marrain P. Combined 17α- and 18-hydroxylase deficiency associated with complete male pseudohermaphroditism and hypoaldosteronism.  J Clin Endocrinol Metab. 1978;  46 236-246
• 32 Waldhäusl W, Kleinberger G, Korn A, Dudczak R, Bratusch-Marrain P, Nowotny P. Severe hyperglycemia: effects of rehydration on endocrine derangements and blood glucose concentration.  Diabetes. 1979;  28 577-584
• 33 World Health Organization Study Group .Diabetes Mellitus. WHO Technical Report Series 727. Geneva, Switzerland; World Health Organization 1985
• 34 Young W F. Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota.  Endocr Metab Clin North Am. 2000;  29 159-185